Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.52 |
| ▸ | LTA4H | P09960 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28256389 | 1.00 | ACE (0.60) | ACEKMT2AL3MBTL1SLC6A2ACE2 | |
| SCHEMBL30112895 | 0.92 | SLC6A2 (0.57) | ACEKMT2AL3MBTL1SLC6A2 | |
| SCHEMBL30052910 | 0.91 | ACE (0.60) | ACESLC6A2ACE2LTA4H | |
| SCHEMBL31632671 | 0.91 | ACE (0.60) | ACESLC6A2ACE2LTA4H | |
| SCHEMBL5275753 | 0.89 | DPP4 (0.51) | ACEKMT2AL3MBTL1SLC6A2ACE2 | |
| SCHEMBL5275743 | 0.89 | DPP4 (0.51) | ACEKMT2AL3MBTL1SLC6A2ACE2 | |
| SCHEMBL9478081 | 0.89 | CALCRL (0.53) | ACESLC6A2ACE2 | |
| SCHEMBL9478089 | 0.89 | CALCRL (0.53) | ACESLC6A2ACE2 | |
| SCHEMBL7303271 | 0.87 | ACE (0.61) | ACEKMT2AL3MBTL1ACE2LTA4H | |
| SCHEMBL7383518 | 0.87 | ACE (0.62) | ACEACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885KMT2A 1801/4885L3MBTL1 184/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885KMT2A 4547/4885L3MBTL1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.